World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 22 June 2020
Main ID:  EUCTR2017-002530-23-PT
Date of registration: 21/05/2018
Prospective Registration: Yes
Primary sponsor: MyoKardia, Inc.
Public title: A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscle
Scientific title: A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - EXPLORER-HCM
Date of first enrolment: 17/09/2018
Target sample size: 220
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002530-23
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Belgium Czech Republic Denmark France Germany Israel Italy Netherlands
Poland Portugal Spain United Kingdom United States
Contacts
Name: Clinical Trial or Medical Inquiries   
Address:  1000 Sierra Point Parkway CA 94005 Brisbane United States
Telephone: +16507410900
Email: medinfo@myokardia.com
Affiliation:  MyoKardia, Inc.
Name: Clinical Trial or Medical Inquiries   
Address:  1000 Sierra Point Parkway CA 94005 Brisbane United States
Telephone: +16507410900
Email: medinfo@myokardia.com
Affiliation:  MyoKardia, Inc.
Key inclusion & exclusion criteria
Inclusion criteria:
1.Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent according to federal, local, and institutional guidelines before the first study specific procedure
2.Is at least 18 years old at Screening
3.Body weight is greater than 45 kg at Screening
4.Has adequate acoustic windows to enable accurate TTEs (Refer to Echocardiography Site Instruction Manual)
5.Diagnosed with oHCM consistent with current AACF/AMA and ESC guidelines, ie, satisfy both criteria below (criteria to be documented by
the echocardiography core laboratory):
A.Has unexplained left ventricular (LV) hypertrophy with nondilated ventricular chambers in the absence of other cardiac (eg, hypertension, aortic stenosis) or systemic disease and with maximal LV wall thickness =15 mm (or =13 mm with positive family history of hypertrophic cardiomyopathy [HCM]), as determined by core lab interpretation and
B.Has LVOT peak gradient =50 mmHg during Screening as assessed by echocardiography at rest, after Valsalva maneuver, or postexercise (confirmed by echocardiography core laboratory interpretation)
6.Has documented left ventricular ejection fraction (LVEF) =55% by echocardiography core laboratory read of Screening TTE at rest
7. Has LVOT gradient with Valsalva maneuver at Screening TTE of =30 mmHg, determined by echocardiography core laboratory
8.Has (NYHA) functional Class II or III symptoms at Screening
9.Has documented oxygen saturation at rest =90% at Screening
10.Is able to perform an upright CPET and has a respiratory exchange ratio (RER) =1.0 at Screening per central reading; if the RER is between 0.91 and 1.0, the participant may be enrolled only if it is determined by the central CPET laboratory that peak exercise has been achieved in the subject (the only permitted reasons for subpeak performance are [1] a decrease in systolic blood pressure or [2] severe angina as described in the CPET Laboratory Manual)
11.Female participants must not be pregnant or lactating and, if sexually active, must use one of the following highly effective birth control methods from the Screening visit through 3 months after the last dose of investigational medicinal product (IMP).
• combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation or progestogenonly hormonal contraception associated with inhibition of ovulation by oral, implantable, or injectable route of administration
• intrauterine device (IUD)
• intrauterine hormone-releasing system (IUS)
• bilateral tubal occlusion
• Female is surgically sterile for 6 months or postmenopausal for 1 year. Permanent sterilization includes hysterectomy, bilateral oophorectomy,
bilateral salpingectomy, and/or documented bilateral tubal occlusion at least 6 months prior to Screening. Females are considered postmenopausal
if they have had amenorrhea for at least 1 year or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone levels are in the postmenopausal range. Male partners must also use a contraceptive (eg, barrier, condom or vasectomy)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 187
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 33

Exclusion criteria:
1.Previously participated in a clinical study with mavacamten
2.Hypersensitivity to any of the components of the mavacamten formulation
3.Participated in a clinical trial in which the participant received any investigational drug (or is currently using an investigational device) within 30 days of Screening, or at least 5x the respective elimination half life (whichever is longer)
4.Infiltrative or storage disorder causing CH that mimics oHCM, such as Fabry disease, amyloidosis, or Noonan syndrome with LVH
5.Medical condition that precludes upright exercise stress testing
6.History of syncope within 6 months prior to Screening or history of sustained ventricular tachyarrhythmia with exercise within 6 months prior to Screening
7.History of resuscitated sudden CA (at any time) or history of appropriate ICD discharge/shock for life-threatening VA within 6 months prior to Screening (Note: history of anti-tachycardia pacing (ATP) within 6 months or ever is allowed)
8.Has paroxysmal, intermittent AF with AF present per the investigator's evaluation of the participant's ECG at time of Screening
9.Has persistent/permanent AF not on anticoagulation for at least 4 weeks to Screening &/or not adequately rate controlled within 6 months
prior to Screening
10.Current treatment (within 14 days to Screening) or planned treatment during the study with disopyramide or ranolazine
11.Current treatment (within 14 days prior to Screening) or planned treatment during the study with a combination of ß-blockers and verapamil or a combination of ß-blockers and diltiazem
12.Individuals on ß-blockers, verapamil, or diltiazem, any dose adjustment of that medication <14 days to Screening or any anticipated change in treatment regimen using these medications during the study
13.(Note: Prev. #13 was removed entirely) Successfully treated with ISR (surgical myectomy or percutaneous alcohol septal ablation [ASA])
within 6 months prior to Screening or plans to have either of these treatments during the study
14.ICD placement or pulse generator change within 2 months prior to Screening or planned new ICD placement during study (pulse generator
changes, if needed during the study, are allowed)
15.Has QT interval with Fridericia correction (QTcF) >500 ms at screening or other ECG abnormality considered by investigator to pose risk to participant safety (eg, second-degree atrioventricular block type II)
16.Documented OCAD (>70% stenosis in one or more epicardial coronary arteries) or history of MI
17.Moderate or severe (as per investigator's judgment) AVS at Screening
18.Acute or serious comorbid condition (eg, major infection or hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction) that, in the judgment of the investigator, could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy & safety assessments in the study
19.Has pulmonary disease that limits exercise capacity or systemic arterial oxygen saturation
20.History of malignant disease within 10 years of Screening: see details in protocol
21.Has safety laboratory parameters (chemistry, hematology, coagulation, & urinalysis) outside normal limits (according to the central laboratory reference range) at Screening as assessed by the central laboratory; however, participant with safety laboratory parameters outside normal limits may be included if he or she meets all of the following criteria:
•Safety laboratory


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Hypertrophic Cardiomyopathy
MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Intervention(s)

Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use

Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use

Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use

Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use

Primary Outcome(s)
Main Objective: To compare the effect of a 30-week course of mavacamten with placebo on clinical response comprising of exercise capacity and clinical symptoms in participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
Primary end point(s): Clinical response defined as achieving: 1) An improvement of at least 1.5 mL/kg/min in peak oxygen consumption (pVO2) as determined by CPET and a reduction of one or more class in NYHA Functional Classification or 2) an improvement of 3.0 mL/kg/min or more in pVO2 with no worsening in NYHA Functional Class.
Secondary Objective: To compare the effect of a 30-week course of mavacamten with placebo on symptoms and left ventricular outflow tract (LVOT) obstruction as determined by Doppler echocardiography
To compare the effect of a 30-week course of mavacamten with placebo on exercise capacity, clinical symptoms and Patient Reported Outcomes individually
To assess the safety and tolerability of mavacamten
To assess the pharmacokinetic (PK) characteristics of mavacamten
Timepoint(s) of evaluation of this end point: Week 30
Secondary Outcome(s)
Secondary end point(s): 1. Change from baseline to Week 30 in post-exercise LVOT peak gradient
2. Proportion of participants with at least 1 class improvement in NYHA
functional class from baseline to Week 30
3. Change from baseline to Week 30 in peak oxygen consumption (pVO2) as determined by CPET
4. Change from baseline to Week 30 in patient-reported severity of HCM symptoms as assessed by the HCM Symptom Questionnaire score
5. Change from baseline to Week 30 in participant-reported health related quality of life as assessed by the KCCQ score
Timepoint(s) of evaluation of this end point: 1. Week 30
2. Week 30
3. Week 30
4. Week 30
5. Week 30
6. Week 30
Secondary ID(s)
121904
2017-002530-23-DE
MYK-461-005
NCT03470545
Source(s) of Monetary Support
MyoKardia, Inc.
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 17/09/2018
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history